Teva Pharmaceutical Industries Limited

Prilenia Neurotherapeutics Ltd.

Danit Licht

Muhammad Safadi

Anton Frenkel

Ramy Lidor-Hadas

Eliezer Bahar

Ioana Lovinger

Rachel Cohen

Marina Zholkovsky

Michal Keisar

Avital Laxer

Konstantin Ulanenko

Vladimir Ioffe

Ulf Tomas Fristedt

The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.

High concentration dosage forms of pridopidine

The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan.

R(+)-N-formyl-propargyl-aminoindan

The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof.

R(+)-N-methyl-propargyl-aminoindan

The subject invention provides a pharmaceutical composition containing laquinimod or a pharmaceutically acceptable salt thereof, and a compound of N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide or a salt thereof.

N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof

Growing community of inventors

Giv′at-Shmuel, Israel

Danit Licht